Neuroblastoma is a paediatric solid tumour with poor survival rates among patients within
the high-risk group, despite advances in therapy. Although chimeric antigen receptor (CAR) …

High-risk neuroblastoma comprises nearly half of all neuroblastoma and have a long-term
survival of< 50%. Patients> 18 months with International Neuroblastoma Staging System …

Chimeric antigen receptors (CARs) combine T-cell activation with antibody-mediated tumor
antigen specificity, bypassing the need for T-cell receptor (TCR) ligation. A limitation of CAR …

C07K16/3076—Immunoglobulins [IGs], eg monoclonal or polyclonal antibodies against
material from animals or humans against receptors, cell surface antigens or cell surface …

Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma of childhood, has a low
mutational burden with few actionable somatic targets. Fibroblast growth factor receptor 4 …

Résumé Les neuroblastomes de haut risque représentent près de la moitié des cas de
neuroblastome et leur survie à long terme est inférieure à 50% malgré des traitements …

ABSTRACT The 16th Annual Meeting of the Association for Cancer Immunotherapy (CIMT),
Europe's largest meeting series of its kind, took place in Mainz, Germany from 15–17 May …

High risk neuroblastoma poses a significant clinical problem in paediatric oncology and new
treatment strategies are needed. Antibody-derived bispecific T cell engagers (BiTEs) and …

Gamma delta (γδ) T cells are a unique subset of lymphocytes that combine both innate and
adaptive immune properties. They are primed for rapid function including tumour cell …

Myeloma remains largely incurable and there is an unmet need for new therapies. B-cell
maturation antigen (BCMA) is an attractive therapeutic target due to its restricted expression …